



Patient Care + Research + Clinical Trials

**Dr. Tom Elliott MBBS, FRCPC**  
**Medical Director**

400 - 210 W Broadway  
Vancouver, BC  
V5Y 3W2 Canada

phone: 604.683.3734  
fax: 604.628.3821  
email: moa@bcdiabetes.ca

## **TACT2 - RCT of chelation Rx vs pbo in diabetes post heart attack (MI)**

### **Hypothesis:**

Heavy metal pollutants (principally lead) are a major cardiovascular risk factor - removing lead from the blood with EDTA will reduce all-cause mortality.

### **The Science**

[2013 Circulation Type 2 diabetes substudy: 41% reduction in MACE, 43% reduction in death](#)

[2013 JAMA paper showing modest overall benefits post MI \(37% diabetic\)](#)

[2018 Lancet epidemiology paper indicating lead as risk factor for cardiovascular death](#)

[2015 announcement of initial NIH funding for TACT2](#)

[background on PI Tony Lamas & history of final \\$37M NIH funding](#)

[TACT2 study website](#)

[TACT2 clinicaltrials.org listing](#)

[TACT2 protocol](#)

[BCDiabetes.ca post 2018-Aug-30](#)

### **Location for study**

BCDiabetes 400 - 210 West Broadway, Vancouver, V5Y 3W2, ph 604-683-3734 ext 7013

email: msharbin@bcdiabetes.ca

### **Eligibility:**

Type 1 or Type 2 diabetes, age 50+

Previous myocardial infarction (with good documentation)

Serum creatinine < 176

### **Study Design & Sponsor:**

multicentre RCT (United States & Canada); sponsor = US National Institutes of Health

### **Intervention:**

Calcium disodium edetate 3 g (or placebo) IV infusion over 3 hours weekly for 40 weeks

**Odds of getting placebo:** 50%

**Reimbursement:** \$50 cash at every study visit to cover travel and time related expenses (see

<https://goo.gl/1r224f>)

